Cargando…

Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia

BACKGROUND: Capillary leak syndrome (CLS) is a rare condition characterized by recurrent episodes of generalized edema and severe hypotension associated with hypoproteinemia. Interleukin-11 (IL-11) is a promising therapeutic agent for thrombocytopenia. A direct correlation between IL-11 and CLS has...

Descripción completa

Detalles Bibliográficos
Autores principales: Kai-Feng, Wang, Hong-Ming, Pan, Hai-Zhou, Lou, Li-Rong, Shen, Xi-Yan, Zhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118946/
https://www.ncbi.nlm.nih.gov/pubmed/21619578
http://dx.doi.org/10.1186/1471-2407-11-204
_version_ 1782206522615398400
author Kai-Feng, Wang
Hong-Ming, Pan
Hai-Zhou, Lou
Li-Rong, Shen
Xi-Yan, Zhu
author_facet Kai-Feng, Wang
Hong-Ming, Pan
Hai-Zhou, Lou
Li-Rong, Shen
Xi-Yan, Zhu
author_sort Kai-Feng, Wang
collection PubMed
description BACKGROUND: Capillary leak syndrome (CLS) is a rare condition characterized by recurrent episodes of generalized edema and severe hypotension associated with hypoproteinemia. Interleukin-11 (IL-11) is a promising therapeutic agent for thrombocytopenia. A direct correlation between IL-11 and CLS has never been reported previously, particularly in patients with hepatic carcinoma. CASE PRESENTATION: We describe two cases of CLS after IL-11 administration in two males with thrombocytopenia. Case 1 was a 46-year-old man with recurrence of hepatic carcinoma who was treated with IL-11 (3 mg per day). After four days of therapy, hypotension and hypoproteinemia were detected. The chest X-ray and B ultrasound of the abdomen showed pleural effusion and ascites. IL-11 was then discontinued, fluid resuscitation was performed, and fresh frozen plasma and packed red blood cells were transfused into this patient. The patient had recovered after 19 days of treatment. Case 2 was a 66-year-old man who had undergone radiofrequency ablation (RFA) for hepatic carcinoma. He was treated with IL-11 (3 mg per day) for thrombocytopenia. After two days of therapy, this patient complained of dyspnea with bilateral edema of the hands. Laboratory values showed hypoproteinemia. IL-11 was stopped and human albumin was transfused at a rate of 10 g per day. On the 4(th )day, fluid resuscitation was performed. The patient had recovered after treatment for two weeks. CONCLUSIONS: The detection of IL-11-induced CLS supports the hypothesis that CLS could be a severe side effect of IL-11 treatment in some patients. These two case reports also demonstrate that patients with hepatic carcinoma who experience this rare form of CLS after treatment with IL-11 seem to respond to a therapeutic regimen that involves hydroxyethyl starch, albumin, and diuretic therapy. Liver cancer patients might be more susceptible to CLS because of poor liver function and hypersplenia. In addition, bleeding after RFA might be a further inducer of CLS.
format Online
Article
Text
id pubmed-3118946
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31189462011-06-22 Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia Kai-Feng, Wang Hong-Ming, Pan Hai-Zhou, Lou Li-Rong, Shen Xi-Yan, Zhu BMC Cancer Case Report BACKGROUND: Capillary leak syndrome (CLS) is a rare condition characterized by recurrent episodes of generalized edema and severe hypotension associated with hypoproteinemia. Interleukin-11 (IL-11) is a promising therapeutic agent for thrombocytopenia. A direct correlation between IL-11 and CLS has never been reported previously, particularly in patients with hepatic carcinoma. CASE PRESENTATION: We describe two cases of CLS after IL-11 administration in two males with thrombocytopenia. Case 1 was a 46-year-old man with recurrence of hepatic carcinoma who was treated with IL-11 (3 mg per day). After four days of therapy, hypotension and hypoproteinemia were detected. The chest X-ray and B ultrasound of the abdomen showed pleural effusion and ascites. IL-11 was then discontinued, fluid resuscitation was performed, and fresh frozen plasma and packed red blood cells were transfused into this patient. The patient had recovered after 19 days of treatment. Case 2 was a 66-year-old man who had undergone radiofrequency ablation (RFA) for hepatic carcinoma. He was treated with IL-11 (3 mg per day) for thrombocytopenia. After two days of therapy, this patient complained of dyspnea with bilateral edema of the hands. Laboratory values showed hypoproteinemia. IL-11 was stopped and human albumin was transfused at a rate of 10 g per day. On the 4(th )day, fluid resuscitation was performed. The patient had recovered after treatment for two weeks. CONCLUSIONS: The detection of IL-11-induced CLS supports the hypothesis that CLS could be a severe side effect of IL-11 treatment in some patients. These two case reports also demonstrate that patients with hepatic carcinoma who experience this rare form of CLS after treatment with IL-11 seem to respond to a therapeutic regimen that involves hydroxyethyl starch, albumin, and diuretic therapy. Liver cancer patients might be more susceptible to CLS because of poor liver function and hypersplenia. In addition, bleeding after RFA might be a further inducer of CLS. BioMed Central 2011-05-27 /pmc/articles/PMC3118946/ /pubmed/21619578 http://dx.doi.org/10.1186/1471-2407-11-204 Text en Copyright ©2011 Kai-Feng et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kai-Feng, Wang
Hong-Ming, Pan
Hai-Zhou, Lou
Li-Rong, Shen
Xi-Yan, Zhu
Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia
title Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia
title_full Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia
title_fullStr Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia
title_full_unstemmed Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia
title_short Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia
title_sort interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118946/
https://www.ncbi.nlm.nih.gov/pubmed/21619578
http://dx.doi.org/10.1186/1471-2407-11-204
work_keys_str_mv AT kaifengwang interleukin11inducedcapillaryleaksyndromeinprimaryhepaticcarcinomapatientswiththrombocytopenia
AT hongmingpan interleukin11inducedcapillaryleaksyndromeinprimaryhepaticcarcinomapatientswiththrombocytopenia
AT haizhoulou interleukin11inducedcapillaryleaksyndromeinprimaryhepaticcarcinomapatientswiththrombocytopenia
AT lirongshen interleukin11inducedcapillaryleaksyndromeinprimaryhepaticcarcinomapatientswiththrombocytopenia
AT xiyanzhu interleukin11inducedcapillaryleaksyndromeinprimaryhepaticcarcinomapatientswiththrombocytopenia